VSY Biotechnology touts injections for joint disease

By Gokhan Ergocun

ISTANBUL

Dutch-based health firm VSY Biotechnology has developed innovative new intra-articular injections to fight degenerative joint disease, it said on Monday.

"Reviscon, Reviscon Plus (32 mg), and Reviscon Mono (48 mg) have been developed in different concentrations in line with patient requirements," said the company in a written statement.

The products were developed for orthopedics, physical treatment, and rehabilitation, according to the statement.

The injections, certified by international quality institutions, can only be administrated to patients by medical professionals, the company noted.

"Reviscon intra-articular solution contains Sodium Hyaluronate, which was developed as a result of intense studies in the R&D Center of VSY Biotechnology as a component fully compatible with the human body," it underlined.

The injections were first introduced to orthopedic physicians in 2015.

VSY Biotechnology, a firm specializing in ophthalmology, is among a handful of companies worldwide that can produce intra-articular injections.

According to the company, VSY Biotechnology serves more than 60 countries around the globe, while its product range includes intra-ocular lenses, viscoelastic, cartridge, injector systems, and intra-articular injections.